1 Both medications have demonstrated cardiovascular safety and benefit in large, long-term trials
Collectively, the medical community, and society as a whole, have failed to acknowledge the biological nature of obesity, as well as the reality that it contributes to many years of disability and causes serious diseases
Pancreatitis and gallbladder disease, though uncommon, are recognised risks associated with GLP-1 receptor agonist use, as documented in the Summary of Product Characteristics (SmPC) for licensed agents in this class (such as semaglutide)
It is that maintaining the gains requires sustained support
Strategies for Managing Nausea and Digestive Discomfort To deal with stomach side effects, try changing your diet and maybe the timing of your medicine